DoD Defense Medical Research and Development Program – Battlefield Wound Management and Infection Research (BWMIR) Award – LOI
Academic Unit: inquire with unit
Memorial Deadline: RIS review not required for LOI
External Deadline: Thursday 20th, October 2022
Pre-Proposal/Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET),
October 20, 2022
Proposal/Application Submission Deadline: 11:59 p.m. ET, November 16, 2022
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Funding Opportunities/Program Announcements and General Application Instructions which can be found on the Grants.gov website (https://Grants.gov). A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
The MIDRP strives to defeat infection by developing solutions to prevent, treat, and diagnose
naturally occurring infectious disease threats to eliminate their impacts on operational readiness
of DOD personnel. Prevention is the most desirable infectious disease countermeasure because
it prevents disease from occurring (versus treatment post-infection), is the most cost-effective
approach, and reduces casualty rates. Improved diagnosis and treatment of infectious disease
casualties is necessary to protect the U.S. Armed Forces. Due to the ever-increasing resistance to
presently available treatments, continued countermeasure developments need to be pursued. The
vision of the MIDRP wound infections capability area is to conduct basic and applied research
leading to the development of rapid identification, prevention, and effective treatment solutions
to mitigate complications from multidrug-resistant wound infections in multi-domain operations
(MDOs) and during prolonged care. However, without understanding how current standard of
care interventions work best to prevent, delay, or treat infection, MIDRP cannot lead and
develop new medical countermeasures.
Additional information can be found here.